Last reviewed · How we verify

POMALIDOMIDE — Competitive Intelligence Brief

POMALIDOMIDE (POMALIDOMIDE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thalidomide Analog [EPC].

marketed Thalidomide Analog [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

POMALIDOMIDE (POMALIDOMIDE).

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
POMALIDOMIDE TARGET POMALIDOMIDE marketed Thalidomide Analog [EPC] 2013-01-01
Pomalyst pomalidomide Bristol-Myers Squibb marketed Thalidomide Analog [EPC] Protein cereblon 2013-01-01
LENALIDOMIDE LENALIDOMIDE marketed Thalidomide Analog [EPC] 2005-01-01
Revlimid lenalidomide Bristol-Myers Squibb marketed Thalidomide analogue Cereblon (component of cullin ring E3 ubiquitin ligase enzyme complex) 2005-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thalidomide Analog [EPC] class)

  1. · 2 drugs in this class
  2. Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). POMALIDOMIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl43452. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: